| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H19N5O2 |
| Molar mass | 289.339 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Etazolate (SQ-20,009,EHT-0202) is ananxiolyticdrug which is apyrazolopyridinederivative and has uniquepharmacological properties.[1][2][3] It acts as apositive allosteric modulator of theGABAA receptor at thebarbituratebinding site,[4][5][6][7] as anadenosineantagonist of theA1 andA2 subtypes,[8] and as aphosphodiesterase inhibitor selective for thePDE4isoform.[9][10][11] It is currently inclinical trials for the treatment ofAlzheimer's disease.[12]